The emerging role of the HTRA1 protease in brain microvascular disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of molecular mechanisms and proteomic studies without clinical trial or systematic review methodology
PubMed 39081996 · doi:10.3389/frdem.2023.1146055
What was done
This narrative review synthesizes genetic, mechanistic, and proteomic findings examining the role of high temperature requirement protein A1 (HTRA1)—a secreted serine protease that degrades matrisomal substrates—in the pathogenesis of cerebral small-vessel diseases, including CARASIL, CADASIL, and cerebral amyloid angiopathy.
What was found
The abstract reports no quantitative metrics, effect sizes, or participant numbers. It notes that genetic loss of HTRA1 function causes CARASIL, while recent proteomic investigations show HTRA1 is sequestered and functionally impaired within pathological protein aggregates in CADASIL and cerebral amyloid angiopathy.
Why it matters
Extracellular matrix accumulation and vessel wall thickening are hallmark features of vascular dementia; identifying HTRA1 dysfunction highlights a potential shared molecular target across diverse hereditary and age-related microvascular pathologies.
Limits
As a narrative review, it presents no original clinical data, patient cohorts, or systematic search methodology. Quantitative findings, comparative risk estimates, and direct evidence of therapeutic modification targeting HTRA1 in humans are not provided in the abstract.
Cited by
- supports CARASIL is a genetic form of small vessel disease caused by HTRA1 mutations that exhibits white matter disease, microbleeds, lacunes, and blood-brain barrier dysfunction.